Table 1 Summary of available clinicopathologic features of NENs (N = 17).
From: Clinical and genomic analyses of neuroendocrine neoplasms of the breast
Features | NET (N = 6) | NEC (N = 11) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Case no. | NEN-1 | NEN-4 | NEN-11 | NEN-13 | NEN-14 | NEN-17 | NEN-2 | NEN-3 | NEN-5 | NEN-6 | NEN-7 | NEN-8 | NEN-9 | NEN-10 | NEN-12 | NEN-15 | NEN-16 |
Gender/Age | F/47 | F/60 | F/32 | F/54 | F/73 | F/48 | F/75 | F/52 | F/35 | F/41 | F/52 | F/59 | F/46 | F/49 | F/53 | F/49 | F/25 |
Laterality | L | R | R | R | R | R | R | R | L | L | L | R | R | L | L | R | R |
Menopausal status | Pre | Post | Pre | Pre | Post | Pre | Post | Post | Pre | Pre | Post | Post | Pre | Pre | Post | Pre | Pre |
cTNM stage | I | IIA | IIIC | IIA | I | I | IIA | IIA | IIB | IIB | IIA | IIA | IIIC | IIIC | IIIC | IIIA | IIA |
pT | 1 | 2 | 2 | 2 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 |
pN | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 3 | 3 | 2 | 2 | 0 |
ER status | - | + | + | + | + | + | + | + | + | + | + | + | + | + | + | - | + |
PR status | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | - | + |
HER2 status | - | - | - | - | - | - | - | - | - | + | - | + | - | + | + | + | - |
Ki67 (%) | 30 | 35 | 3 | 20 | 10 | 5 | 30 | 30 | 80 | 50 | 75 | 75 | 30 | 50 | 45 | 35 | 30 |
CgA (%) | 5 | 0 | 60 | 0 | 30 | 90 | 5 | 60 | 95 | 5 | 90 | 0 | 5 | 0 | 10 | 10 | 80 |
Syn (%) | 90 | 95 | 90 | 90 | 90 | 90 | 95 | 100 | 95 | 95 | 0 | 95 | 90 | 90 | 90 | 95 | 90 |
LVI | N | N | N | N | N | N | N | Y | Y | N | N | N | Y | Y | N | Y | N |
Surgery type | Ma | Ma | Ma | Ma | Ma | Lu | Ma | Ma | Ma | Ma | Ma | Lu | Ma | Ma | Ma | Ma | Ma |
Chemotherapy | Y | N | Y | N | N | N | N | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y |
Radiotherapy | N | N | Y | N | N | N | N | N | Y | Y | N | N | Y | Y | Y | Y | Y |
Endocrine therapy | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | N | Y | Y | Y | N | Y |
Anti-HER2 therapy | N | N | N | N | N | N | N | N | N | N | N | Y | N | N | N | N | N |
Follow-up (months) | NED (44) | NED (29) | NED (55) | NED (11) | NED (1) | NED (18) | NED (61) | NED (59) | NED (43) | CM/AM (39) | NED (63) | NED (3) | NED (37) | BM (4) DOD (32) | NED (46) | NED (67) | NED (5) |
